Metabolic syndrome: Comparison of biological parameters among various definitions;Le syndrome métabolique: Comparaison des paramètres biologiques dans différentes définitions

Immuno-Analyse et Biologie Specialisee

Volumn 19, Issue 4, 2004, Pages 188-194

  Luyckx, F H ^a   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Biologie clinique; Clinical biology; Insulin resistance; Insulinor sistance; Lipides; Lipids; Metabolic syndrome; Obesity; Syndrome m tabolique; Syndrome X

Indexed keywords

ANALYTICAL PARAMETERS; ARTERIAL PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 4644278147     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2004.03.008     Document Type: Short Survey

References (41)

1. Aguilar-Salinas C.A., Rojas R., Gomez-Perez F.J., et al. Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome (letter). Diabetes Care. 26:2003;1635
2. Alberti K.G.M.M., Zimmet P.Z. for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I, Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med. 15:1998;539-553
3. Balkau B., Charles M.A. Comment on the provisional report from the WHO consultation. Diabetic Med. 16:1999;442-443. European Group for the Study of Insulin Resistance (EGIR)
4. Balkau B., Vernay M., Mhamdi L., et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. Diabetes Metab. 29:2003;526-532. The French DESIR. study
5. DeBacker G., Ambrosioni E., Borch-Johnsen K., et al. Executive Summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 24:2003;1600-1609
6. Després J.P., Lemieux I., Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 322:2001;716-720
7. Després J.P., Lamarche B., Mauriège P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:1996;952-957
8. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 9:2003;237-252
9. European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 28:2002;364-376
10. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
11. Ford E.S., Giles W.H. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 26:2003;575-581
12. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. Findings from the third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359
13. Groop L., Ohro-Melander M. The dysmetabolic syndrome. J Intern Med. 250:2001;105-120
14. Grundy S.M., Brewer H.B. Jr, Cleeman J.I., et al. Definition of metabolic syndrome. Circulation. 109:2004;433-438. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition
15. Hanley A.J.G., Wagenknecht L.E., D'Agostino R.B., et al. Identification of subjects with insulin resistance and β-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes. 52:2003;2740-2747
16. Hollenbeck C., Reaven G.M. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 64:1987;1169-1173
17. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689
18. Kaplan N.M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 149:1989;1514-1520
19. Kylin E. Studien ueber das Hypertonie-Hyperglykämie- Hyperurikämiesyndrom. Zentralblatt fuer Innere Medizin. 44:1923;105-127
20. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2002;2709-2716
21. Lamarche B., Tchernof A., Mauriège P., et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 279:1998;1955-1961
22. Lemieux I., Pascot A., Couillard C., et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small dense LDL) in men. Circulation. 102:2000;179-184
23. Lemieux I., Després J.P. Obesity and hyperlipidemia. Kopelman P.G. Management of obesity and related disorders. 2001;45-63 Martin Dunitz, London, UK
24. Luyckx F.H., Scheen A.J. Exploration et suivi biologique d'un patient obèse. Immuno-Anal Biol Spec. 15:2000;250-254
25. Luyckx F.H., Scheen A.J. L'hyperglycémie provoquée par voie orale. 1. De la controverse à un plaidoyer pour sa place en biologie clinique. Immuno-Anal Biol Spec. 18:2003;126-132
26. Luyckx F.H., Scheen A.J., Desaive C., et al. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes Metab. 24:1998;355-361
27. Luyckx F., Scheen A.J., Gielen J., Lefèbvre P.J. Comment j'explore. Le syndrome d'insulinorésistance grâce à ses marqueurs biologiques. Rev Med Liège. 52:1997;686-691
28. Luyckx F.H., Scheen A.J., Lefèbvre P.J. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 26:2000;98-106
29. Marques-Vidal P., Mazoyer E., Bongard V., et al. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care. 25:2002;1371-1377
30. Meigs J.B. Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol. 152:2000;908-911
31. Modan M., Halkin H., Almog S., et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest. 75:1985;807-817
32. Rantala A.O., Kauma H., Lilja M., et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 245:1999;163-174
33. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607
34. Reaven G.M. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 44:1993;121-131
35. Scheen A.J. Insulin resistance syndrome and atherosclerotic cardiovascular disease. Acta Clin Belg. 51:1996;65-69
36. Scheen A.J. Le syndrome X, à la croisée des maladies métaboliques et cardio-vasculaires. Rev Med Liège. 53:1998;29-32
37. Scheen A.J., Luyckx F.H. Medical aspects of obesity. Acta Chir Belg. 99:1999;135-139
38. Scheen A.J., Luyckx F.H. Le syndrome métabolique: définitions et données épidémiologiques. Rev Med Liège. 58:2003;479-484
39. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 106:2002;3143-3421
40. Vague J. The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr. 4:1956;20-28
41. Consultation WHO. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I, Diagnosis and classification of diabetes mellitus. World Health Organisation, non-communicable disease surveillance. Geneva, 1999